--论文--
1. Wu D, Chen L, Liao W, Ding Y, Zhang Q, Li Z, Liu L. Fascin1 expression predicts poor prognosis in patients with nasopharyngeal carcinoma and correlates with tumor invasion. Ann Oncol. 2010 Mar;21(3):589-596. doi:10.1093/annonc/mdp333. Epub 2009 Sep 16. (IF=65.4)
2. Zhang YP, Guo ZQ, Cai XT, Rong ZX, Fang Y, Chen JQ, Zhuang KM, Ruan MJ, Ma SC, Lin LY, Han DD, Li YS, Wang YY, Wang J, Cao CH, Tang XR, Xie QK, Chen Y, Lin Y, Tan JL, Yu ZH, Wu ZN, Wei W, Zheng DY, Zeng YJ, Ruan YC, Xu ZP, Gu JZ, Xiao LS, Liu L, Guan J, Bai X, Wu DH (co-corresponding author), Dong ZY. PAI-1-driven SFRP2(high) cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy. Cancer Cell 2025, 43(5): 856-874 e859. (IF=44.5)
3. Cao C, Sun J, Zhang D, Guo X, Xie L, Li X, Wu D (co-corresponding author), Liu L. The long intergenic noncoding RNA UFC1, a target of MicroRNA 34a, interacts with the mRNA stabilizing protein HuR to increase levels of β-catenin in HCC cells. Gastroenterology. 2015 Feb;148(2): 415-26.e18. doi: 10.1053/j.gastro.2014.10.012. Epub 2014 Oct 22. (IF=25.1)
4. Long LL, Ma SC, Guo ZQ, Zhang YP, Fan Z, Liu LJ, Liu L, Han DD, Leng MX, Wang J, Guo XJ, Tan JL, Cai XT, Lin Y, Pan X, Wu DH (co-corresponding author), Bai X, Dong ZY. PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer. Cancer Res. 2023 Feb 15;83(4):568-581. doi: 10.1158/0008-5472. CAN-22-1740. (IF=16.6)
5. Fang Y, Zhan Y, Xie Y, Du S, Chen Y, Zeng Z, Zhang Y, Chen K, Wang Y, Liang L, Ding Y, Wu D (corresponding author). Integration of glucose and cardiolipin anabolism confers radiation resistance of HCC. Hepatology. 2022 Jun;75(6):1386-1401. doi: 10.1002/hep.32177. Epub 2021 Dec 6. (IF=15.8)
6. Bai X, Guo ZQ, Zhang YP, Fan ZZ, Liu LJ, Liu L, Long LL, Ma SC, Wang J, Fang Y, Tang XR, Zeng YJ, Pan X, Wu DH (co-corresponding author), Dong ZY. CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. Nat Commun. 2023 Mar 4;14(1):1247. doi: 10.1038/s41467-023-36892-4. (IF=15.7)
7. Fang Y, Shen ZY, Zhan YZ, Feng XC, Chen KL, Li YS, Deng HJ, Pan SM, Wu DH (co-corresponding author), Ding Y. CD36 inhibits β-catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis. Nat Commun. 2019 Sep 4;10(1):3981. doi: 10.10 38/s41467-019-11662-3. (IF=15.7)
8. Sun Y, Zhou P, Qian J, Zeng Q, Wei G, Li Y, Liu Y, Lai Y, Zhan Y, Wu D (co-corresponding author), Fang Y. Spermine synthase engages in macrophages M2 polarization to sabotage antitumor immunity in hepatocellular carcinoma. Cell Death Differ 2025, 32(3): 573-586. (IF=15.4)
9. Zou X, Zhang D, Song Y, Liu S, Long Q, Yao L, Li W, Duan Z, Wu D (co-corresponding author), Liu L. HRG switches TNFR1-mediated cell survival to apoptosis in Hepatocellular Carcinoma. Theranostics. 2020 Aug 20;10(23):10434-10447. doi: 10.7150/thno.47286. (IF=13.3)
10. Zhang DY, Sun QC, Zou XJ, Song Y, Li WW, Guo ZQ, Liu SS, Liu L, Wu DH (corresponding author). Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2. J Exp Clin Cancer Res. 2020 Oct 29;39(1):229. doi: 10.1186/ s13046-020-01748-y. (IF=12.8)
11. Sun J, Zhu Z, Li W, Shen M, Cao C, Sun Q, Guo Z, Liu L, Wu D (corresponding author). UBE2T-regulated H2AX mono- ubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation. J Exp Clin Cancer Res. 2020 Oct 21;39(1):222. doi: 10.1186/s13046-020-01734-4. (IF=12.8)
12. Deng L, Sun J, Chen X, Liu L, Wu D (corresponding author). Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019 Jul 18;38(1):316. doi: 10.1186/s13046-019-1311-z. (IF=12.8)
13. Zhang DY, Zou XJ, Cao CH, Zhang T, Lei L, Qi XL, Liu L, Wu DH (corresponding author). Identification and Functional Characterization of Long Non-coding RNA MIR22HG as a Tumor Suppressor for Hepatocellular Carcinoma. Theranostics. 2018 Jun 13;8(14):3751-3765. doi: 10.7150/thno.22493. (IF=12.4)
14. Sun X, Cai X, Li S, Pi R, Guo Z, Jiang J, Wang P, Xiong J, Liu Z, Rong Z, Yu Z, Zhang X, Chen J, Han D, Zhang Y, Tan J, Lin Y, Zou Z, Ai H, Kang F, Guo X, Dong Z, Wu D (co-corresponding author), Bai X. High-dose ascorbic acid selectively induces pyroptosis in LKB1-deficient lung cancer and sensitizes immunotherapy. Cell Rep Med 2025, 6(9): 102291. (IF=10.6)
15. Bai X, Wu DH (co-first author), Ma SC, Wang J, Tang XR, Kang S, Fu QJ, Cao CH, Luo HS, Chen YH, Zhu HB, Yan HH, Wu YL, Dong ZY. Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study. J Immunother Cancer. 2020 Jun;8(1):e000381. doi: 10.1136/jitc-2019-000381. (IF=10.6)
16. Zhu Z, Cao C, Zhang D, Zhang Z, Liu L, Wu D (co-corresponding author), Sun J. UBE2T-mediated Akt ubiquitination and Akt/β-catenin activation promotes hepatocellular carcinoma development by increasing pyrimidine metabolism. Cell Death Dis. 2022 Feb 15;13(2):154. doi: 10.1038/s4 1419-022-04596-0. (IF=9.6)
17. Guo XJ, Cai XT, Rong ZX, Zhang YP, Wen YX, Bai X, Wang J, Fu QJ, Guo ZQ, Long LL, Ma SC, Tang XR, Liu L, Guan J, Dong ZY, Wu DH (corresponding author). Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation. BMC Med. 2023 Jan 5;21(1):6. doi: 10.1186/s12916-022-02713-6. (IF=8.3)
18. Ma SC, Bai X, Guo XJ, Liu L, Xiao LS, Lin Y, Tan JL, Cai XT, Wen YX, Ma H, Fu QJ, Leng MX, Zhang YP, Long LL, Guo ZQ, Wu DH (co-corresponding author), Zhou JG, Dong ZY. Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice. BMC Med. 2022 Apr 12;20(1):120. doi: 10.1186/s12916-022-02315-2. (IF=8.3)
19. Rong ZX, Wei W, Zeng Q, Cai XT, Wang YY, Wang J, Luo HS, Xiao LS, Lin JR, Bai X, Zhang YP, Han DD, Dong ZY, Wang W, Wu DH (co-corresponding author), Ma SC. HLA diversity unveils susceptibility and organ-specific occurrence of second primary cancers: a prospective cohort study. BMC Med. 2024 Oct 8;22(1):443. doi: 10.1186/s12916-024-03676-6.（IF=8.3）
20. Li XY, Yan N, Wu YY, Kong RJ, Qiu ZW, Liu SP, Wu DH (co-corresponding author), Cheng H. Neuropilin-1-Targeted Nanomedicine for Spatiotemporal Tumor Suppression through Photodynamic Vascular Damage and Antiangiogenesis. ACS Appl Mater Interfaces. 2024 May 1;16(17):21709-21721. doi: 10.1021/acsami.4c03886. Epub 2024 Apr 23. (IF=8.2)
21. Zou J, Luo H, Zeng Q, Dong Z, Wu D (co-corresponding author), Liu L. Protein kinase CK2α is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT- related genes. J Transl Med. 2011 Jun 25;9:97. doi: 10.1186/1479-5876-9-97. (IF=7.5)
22. Zhou P, Deng Y, Sun Y, Wu D (co-corresponding author), Chen Y. Radiation-sensitive circRNA hsa_circ_0096498 inhibits radiation-induced liver fibrosis by suppressing EIF4A3 nuclear translocation to decrease CDC42 expression in hepatic stellate cells. J Transl Med. 2024 Oct 1;22(1):884. doi: 10.1186/s12967-024-05695-6.（IF=7.5）
23. Lin Y, Zhou X, Yang K, Chen Y, Wang L, Luo W, Li Y, Liao J, Zhou Y, Lei Y, Zhang Y, Wu D (co-corresponding author), Cai L. Protein tyrosine phosphatase receptor type D gene promotes radiosensitivity via STAT3 dephosphorylation in nasopharyngeal carcinoma. Oncogene. 2021 Apr;40(17):3101-3117. doi: 10.1038/s41388-021-01768-8. Epub 2021 Apr 6. (IF=7.3)
24. Liu C, Zhou X, Long Q, Zeng H, Sun Q, Chen Y, Wu D (co-corresponding author), Liu L. Small extracellular vesicles containing miR-30a-3p attenuate the migration and invasion of hepatocellular carcinoma by targeting SNAP23 gene. Oncogene. 2021 Jan;40(2):233-245. doi: 10.1038/s41388-020-01521-7. Epub 2020 Oct 27. (IF=7.3)
25. Hua S, Lei L, Deng L, Weng X, Liu C, Qi X, Wang S, Zhang D, Zou X, Cao C, Liu L, Wu D (corresponding author). miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1. Oncogene. 2018 Mar;37(12):1624- 1636. doi: 10.1038/s41388-017-0057-3. Epub 2018 Jan 16. (IF=7.3)
26. Guo Z, Zhang H, Fu Y, Kuang J, Zhao B, Zhang L, Lin J, Lin S, Wu D (co-corresponding author), Xie G. Cancer-associated fibroblasts induce growth and radioresistance of breast cancer cells through paracrine IL-6. Cell Death Discov. 2023 Jan 13;9(1):6. doi: 10.1038/s41420-023-013 06-3. (IF=7.0)
27. Chen Y, Zhou P, Deng Y, Cai X, Sun M, Sun Y, Wu D. ALKBH5-mediated m6A demethylation of TIRAP mRNA promotes radiation-induced liver fibrosis and decreases radiosensitivity of hepatocellular carcinoma. Clin Transl Med. 2023 Feb;13(2):e1198. doi: 10.1002/ctm2.1198. (IF=6.8)
28. Sheng H, Luo Y, Zhong L, Wang Z, Sun Z, Gao X, He X, Zhu Z, Wu D (co-corresponding author), Sun J, Cao C. Antiangiogenic Treatment Facilitates the Abscopal Effect of Radiation Therapy Combined With Anti-PD-1 in Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2025, 121(2): 534-546. (IF=6.5)
29. Ma SC, Tang XR, Long LL, Bai X, Zhou JG, Duan ZJ, Wang J, Fu QJ, Zhu HB, Guo XJ, Zhang YP, Guo ZQ, Wu D (co-corresponding author), Dong ZY. Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. Oncoimmunology. 2021 Apr 26;10(1):1909296. doi: 10.1080/2162402X .2021.1909296. (IF=6.3)
30. Zhu Z, Linghu D, Luo Y, Sun S, Xie Z, Sun Z, Li C, Zhang Q, Yao Q, Wu D (co-corresponding author), Cao C, Sun J. Subacute dibutyl phthalate exposure impairs hepatic T cells and facilitates hepatitis B progression in mouse liver. Ecotoxicol Environ Saf 2025, 299: 118398. (IF=6.1)
31. Zhou X, Du J, Liu C, Zeng H, Chen Y, Liu L, Wu D. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint. Front Immunol. 2021 Jul 9;12:688215. doi: 10.3389/fimmu.2021.688215. (IF=5.9)
32. Tan Z, Zhou P, Zhu Z, Wang Y, Guo Z, Shen M, Xiao Y, Shen W, Wu D. Upregulated long noncoding RNA LincIN promotes tumor progression via the regulation of nuclear factor 90/microRNA-7/HOXB13 in esophageal squamous cell carcinoma. Int J Mol Med. 2021 May;47(5):78. doi: 10.3892/ijmm.2021.4911. Epub 2021 Mar 11. PMID: 33693959; PMCID: PMC7979264. (IF=5.8)
33. Huang Y, Sheng H, Xiao Y, Hu W, Zhang Z, Chen Y, Zhu Z, Wu D (co-corresponding author), Cao C, Sun J. Wnt/β-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma. Radiother Oncol. 2021 Sep;162:34-44. doi:10.1016/j.radonc.2021.06.034. Epub 2021 Jun 29. PMID: 34214613. (IF=5.3)
34. Ren QN, Huang DH, Zhang XN, Wang YN, Zhou YF, Zhang MY, Wang SC, Mai SJ, Wu DH (co-corresponding author), Wang HY. Two somatic mutations in the androgen receptor N-terminal domain are oncogenic drivers in hepatocellular carcinoma. Commun Biol. 2024 Jan 5;7(1):22. doi: 10.1038/s42003-023-05704-2IF: 5.2 Q1 . (IF=5.1)
--基金--
01. 国家自然科学基金（面上项目），82272737 ，KMO/Kyn/AHR信号共调控肿瘤细胞及CD8+T 淋巴细胞介导肝癌辐射抵抗的分子机制，52万元，2023年，在研，第一负责人。
02. 广州市科技计划项目（重点研发计划），2023B03J1237，基于物联网的远程放疗质控系统研发，100万元，2023年，在研，第一负责人。
03. 广东省自然科学基金（面上项目），2023A1515010196，CRTAM介导T细胞Th17/Tc17极化诱发肿瘤放疗联合免疫治疗不良反应的机制研究，10万元，2023年，在研，第一负责人。
04. 广东省区域联合基金（重点项目），2022B1515120035，新型硼递送剂lipo-FBY联合BNCT在肝癌治疗中的功能和机制研究，100万元，2022年，在研，第一负责人。
05. 国家自然科学基金（面上项目），82073394，精胺合成酶SMS通过调控巨噬细胞募集与M2型极化介导肝癌免疫逃逸的分子机制，55万元，2020年，已结题，第一负责人。
06. 国家自然科学基金（面上项目），81872399，SNHG6-003调控外泌体促进肝癌细胞侵袭转移的分子机制，58万元，2018年，已结题，第一负责人。
07. 国家自然科学基金（面上项目），81672756，HIF-1α－UPK1A-AS1－UPK1A正反馈环路对肝癌发生发展的影响及机制，51万元，2016年，已结题，第一负责人。
08. 国家自然科学基金（面上项目），81472711，lincRNA-UFC1在肝癌发生发展中的作用及其机制探讨，74万元，2014年，已结题，第一负责人。
09. 广东省自然科学基金（重点项目）， 2014A030311013，lincRNA-UFC1在miR-34a调控下通过β-catenin参与肝癌侵袭转移的分子机制研究，30万元，2014年，已结题，第一负责人。
10. 国家自然科学基金（面上项目），81172586，HMGB1介导自噬对鼻咽癌放射敏感性的影响及机制研究，62万元，2011年，已结题，第一负责人。
11. 国家自然科学基金（面上项目），30672312，鼻咽癌转移及预后相关基因fascin-1的功能及机制研究，28万元，2009年，已结题，第一负责人。
--指导学生教学表彰--
1. 2021级硕士研究生张效楠及2016级八年制学生马思聪同学分别荣获2024届南方医科大学优秀 毕业生。
2. 2022级博士周佩涛同学被评为2023-2024年度优秀研究生。
3. 2016级八年制学生马思聪同学荣获2024年研究生简历大赛一等奖。
4. 2017级八年制蔡晓庭同学荣获2024年度国际肺癌研究协会（IASLC）Developing Countries Education Award。
5. 张艳培博士后荣获2025年度国际肺癌研究协会（IASLC）International Mentorship Award。